Predictive Oncology 株価情報 (NASDAQ: POAI)

最新ニュース Predictive Oncology (NASDAQ:POAI) 株価情報

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Inc

Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBX#NYSE">RBX</a>) stock is trading higher on Tuesday. The company is anticipated to report 2024 fiscal-year fourth-quarter earnings on Thursday before <a href="https://www.benzinga.com//node/42851942">the market opens</a>.
The Details: Analysts estimate a loss of 45 cents per share and revenue of $1.35 billion for the company&#8217;s fourth-quarter, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. Roblox had previously guided revenue between $935 million and $960 million.
For the 2024 fiscal-year, Roblox expects revenue from $3.54 billion to $3.57 billion, adjusted EBITDA from $125 million to $145 million and free cash flow between $621 million and $636 million.
Ahead of earnings, Citigroup analyst Jason Bazinet maintained a Buy rating on Roblox and raised the price target from&nbsp;$63&nbsp;to&nbsp;$82.
See Also: <a href="https://www.benzinga.com/general/restaurants/25/02/43466529/chipotle-stock-simmers-ahead-of-q4-earnings-bullish-breakout-or-just-sizzle">Chipotle Stock Simmers Ahead Of Q4 Earnings: Bullish Breakout Or Just Sizzle?</a>
RBLX Price Action: At the time of writing, Roblox stock is trading 2.49% higher at $72.44, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

News

Movers

RBLX

TSX:RBX

What's Going On With Roblox Shares Tuesday?

Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) shares are trading lower after the company reported a fourth-quarter 2024 net sales decline of 1% year over year (Y/Y) to $973 million, slightly beating <a href="https://www.benzinga.com/pressreleases/25/02/b43457963/pentair-reports-strong-fourth-quarter-and-full-year-2024-results" target="_blank" rel="noreferrer noopener">the consensus of $972.8 million</a>.
Also, core sales declined by&nbsp;1%&nbsp;Y/Y in the&nbsp;fourth quarter, excluding currency translation, acquisitions, and divestitures.
Gross margin expanded to&nbsp;38.8%&nbsp;from&nbsp;37.2% a year ago in the quarter. Adjusted operating margin expanded 370&nbsp;basis points Y/Y to&nbsp;23.8% in the quarter.
Flow segment sales decreased by&nbsp;5%&nbsp;Y/Y to&nbsp;$360.7 million, Segment income was&nbsp;$73.6 million&nbsp;(+13%&nbsp;Y/Y), and the operating margin was&nbsp;20.4%, an increase of 320&nbsp;bps Y/Y in the quarter.
Water Solutions segment sales were&nbsp;$257.9 million&nbsp;(-4% Y/Y), Segment income was&nbsp;$62.2 million&nbsp;(+21%&nbsp;Y/Y), and ROS was&nbsp;24.1%, up 500 bps Y/Y.
Pool segment sales were&nbsp;$331.4 million&nbsp;(+5%&nbsp;Y/Y), Segment income was&nbsp;$119.4 million&nbsp;(+14%&nbsp;Y/Y), and ROS was&nbsp;33.8%, up 250&nbsp;bps Y/Y.
Adjusted EPS came in at&nbsp;$1.08, surpassing&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$1.01</a>.&nbsp;
For the year, the operating cash flow of continuing operations was&nbsp;$767&nbsp;million, and the free cash flow from continuing operations was&nbsp;$693&nbsp;million.
Dividend: Pentair paid a regular cash dividend of 23 cents per share in the fourth quarter of 2024.
On December 16, 2024, the company announced a quarterly cash dividend of 25 cents per share, payable on Feb. 7, 2025, to shareholders <a href="https://www.benzinga.com/pressreleases/24/12/b42519398/pentair-announces-rate-increase-to-its-quarterly-cash-dividend" target="_blank" rel="noreferrer noopener">of record as of Jan. 24, 2025</a>.
This represents an 8.7% increase from the previous 23 cents per share.
Buyback: In the quarter, Pentair repurchased 0.4 million shares for $50 million. As of Dec. 31, 2024, $450 million remained available under its share repurchase authorization.
Outlook: Pentair forecasts first-quarter adjusted EPS of $1.00-$1.02 (vs. consensus of $1.09)<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">, with sales down 3%-4%</a>.
For 2025, the company expects adjusted EPS of $4.65-$4.80 (vs. street view of $4.82) and sales flat to up 2%.
John L. Stauch, Pentair&#8217;s president and chief executive officer said, &#8221;We expect to continue to invest in key areas across the company and execute on our Transformation initiatives and 80/20 to drive long-term growth, profitability and returns.&#8221;
&#8221;We believe our balanced water portfolio is proving its resilience as Pool is expected to grow offsetting our Flow and Water Solutions residential end markets that remain pressured by higher interest rates. We are confident in our strategy and our ability to control what we can internally while mitigating risk from an uncertain macroeconomic and geopolitical environment near-term.&#8221;
Investors can gain exposure to the stock via&nbsp;Invesco Global Water ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIO#NASDAQ">PIO</a>) and&nbsp;Global X Clean Water ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQWA#NASDAQ">AQWA</a>).
Price Action: PNR shares are down 2% at $100.41 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43463926" target="_blank" rel="noreferrer noopener">Spotify Q4 Earnings: Revenue Beat, Higher ARPU and Premium Growth Drive Profitability, Issues Strong Q1 Outlook</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Equities

Large Cap

Guidance

Dividends

Buybacks

AQWA

Pentair Beats Q4 Estimates, Raises Dividend, Guides Below Expectations For 2025

Citigroup analyst Ariel Rosa maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $561 to $544.

Price Target

Analyst Ratings

SAIA

Citigroup Maintains Buy on Saia, Lowers Price Target to $544

Transdigm Exec Says Optimistic That Boeing's Going To Get Back Up To The Rate Of 38, Today We're Probably Seeing About Half Of That

WIIM

SUPN

Supernus Pharmaceuticals shares are trading higher after the company received FDA approval of ONAPGO for Parkinson's disease.

On Tuesday, Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) reported fourth-quarter sales of $40.80 billion. That&#8217;s up 3.41% year-over-year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $39.13 billion</a>.
Centene earned an adjusted EPS of 80 cents during the quarter, <a href="https://www.benzinga.com/pressreleases/25/02/n43456894/centene-corporation-reports-2024-results" target="_blank" rel="noreferrer noopener">beating the consensus of 49 cents</a>. For the fourth quarter of 2024, premium and service revenues increased 3% to $36.3 billion from $35.3 billion in the comparable period of 2023. 
A health benefits ratio (HBR) of 89.6% for the fourth quarter of 2024 represents an increase from 89.5% in the comparable period in 2023. The increase was primarily driven by higher acuity in Medicaid, which resulted from the redetermination process.
The company also saw Membership increases of 12% in Marketplace and 50% in Medicare PDP, compared to the fourth quarter of 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
&#8220;Despite a year of unprecedented industry headwinds, Centene demonstrated significant operational improvements, strengthened our talent bench, and delivered on our financial commitments in 2024,&#8221; said CEO Sarah London. 
Centene reported 28.6 million members as of December 31, up from 27.5 million in 2023.
Enrollment in its Medicaid plans dipped as redeterminations completed, from 14.5 million to 13 million. Marketplace coverage increased year over year, growing from 3.9 million to 4.4 million.
Guidance: Centene said it will raise its premium and service revenue guidance window by $4 billion. The company now expects to bring in between $158 billion and $160 billion for 2025.
In December, the company outlined 2025 guidance with premium and service revenues of $154 billion to $156 billion. The company expects total revenue between <a href="https://www.benzinga.com/general/health-care/24/12/42467798/why-is-insurance-firm-centene-stock-trading-higher-on-thursday" target="_blank" rel="noreferrer noopener">$166.5 billion and $169.5 billion</a>.
Centene reaffirms FY2025 adjusted EPS of greater than&nbsp;$7.25 compared to consensus of $7.22.
Price Action: Centene stock is down 5.13% at $61.50 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43464103/enterprise-products-beats-q4-forecasts-targets-6-billion-in-2025-expansions" target="_blank" rel="noreferrer noopener">Enterprise Products Beats Q4 Forecasts, Targets $6 Billion In 2025 Expansions</a></li>
</ul>

Health Care

Trading Ideas

Insurance

General

Insurance Firm Centene Sees Q4 Revenue Boost, Sticks To Annual Forecast

Citigroup analyst Tyler Radke maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Buy and lowers the price target from $1432 to $1426.

Citigroup Maintains Buy on ServiceNow, Lowers Price Target to $1426

BABA

BEKE

BIDU

FUTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading higher despite global trade tensions. China imposted tariffs and added two US companies to its 'Unreliable Entity List.' Additionally, US-listed names may be on watch amid China's Lunar New Year.

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1024" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04145836/image.png" alt="" class="wp-image-5394" style="width:684px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04145836/image.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04145836/image-300x300.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04145836/image-150x150.png 150w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/04145836/image-768x768.png 768w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Complexities of Share Buyback Programs</h2>
While share buybacks can enhance shareholder value by reducing the number of outstanding shares and boosting earnings-per-share (EPS) ratios, they also introduce significant risks and challenges for companies. These risks are multifaceted, encompassing financial, operational, and market-related factors that must be carefully managed to ensure successful execution.
One of the primary concerns is the irrevocability of many buyback contracts. Companies often enter into agreements with brokers that commit them to purchasing a fixed amount of shares over a specified period. However, unforeseen circumstances such as mergers and acquisitions (M&amp;A), economic shocks, or changes in business strategy may necessitate pausing or canceling these programs. Terminating such agreements can prove costly, particularly during periods of market volatility when unwinding accumulated portfolios incurs substantial losses.
For example, during the onset of the COVID-19 pandemic in 2020, several prominent UK companies, including Diageo, BP, and Pearson, were forced to pause or cancel multi-billion-dollar buyback programs. This decision was driven by the need to preserve capital amid uncertain economic conditions. However, terminating these programs required unwinding existing positions at fair value, resulting in significant costs due to adverse market movements.
<h2 class="wp-block-heading">Market Volatility of Share Buybacks and Its Impact</h2>
Volatility plays a critical role in the mechanics of share buybacks but poses unique challenges for issuers. Banks executing buyback programs typically require fluctuations in stock prices to generate discounts, allowing them to time purchases effectively. While this approach maximizes cost efficiency, it introduces potential conflicts of interest between banks and their clients.
Critics argue that brokers prioritize their own profitability over the issuer&#8217;s broader objectives. Such as maintaining stable cash flow management or signaling confidence to shareholders. For instance, during <a href="https://www.globaltrading.net/the-challenge-of-share-buybacks/">ING Group&#8217;s </a>€1.5 billion buyback program in 2023, the broker reportedly delayed transferring shares until after the company paid dividends, enabling it to capture additional income despite contractual losses on the buyback agreement. Such practices highlight the complexities and inherent risks associated with dynamic hedging strategies employed by banks.
<h2 class="wp-block-heading">Regulatory Constraints and Disclosure Requirements</h2>
Regulatory frameworks governing share buybacks vary significantly across jurisdictions, further complicating their execution. In Europe, Market Abuse Regulation (MAR) mandates strict disclosure requirements, obliging companies to announce their intentions ahead of time and report daily transaction details. While these rules aim to maintain market integrity, they limit flexibility and expose issuers to information leakage risks.
In contrast, U.S. regulations under <a href="https://www.investopedia.com/terms/r/rule-10b5-1.asp#:~:text=Rule%2010b5%2D1%20allows%20company,by%20a%20formula%20or%20metrics.">Rule 10b-51</a> provide greater flexibility, allowing brokers to execute buybacks during pre-earnings blackout periods without violating insider trading laws. However, this discretion comes with volume restrictions designed to prevent market manipulation. Companies must carefully balance compliance with regulatory obligations against their strategic objectives, ensuring transparency while minimizing potential disruptions to share price stability.
<h2 class="wp-block-heading">Strategic Alignment and Flexibility</h2>
To address these challenges, companies are increasingly demanding more flexible buyback structures that align with their long-term goals. Pearson, a UK-listed education software company, exemplifies this trend by introducing a hybrid model combining performance-based and fixed-fee elements. Partnering with Citi, Pearson incorporated mechanisms allowing it to override purchase instructions or cancel the program entirely if unforeseen circumstances arise. Such as M&amp;A opportunities or external shocks.
This shift reflects growing recognition of the uncertainties inherent in modern financial markets. By prioritizing adaptability and incorporating shorter-term programs, companies can better navigate volatile environments while preserving strategic flexibility. As Ali Farhan, Director of Strategic Equity Solutions at Citi, notes: &#8220;Since COVID, we've seen more buybacks run on a quarterly basis, which are shorter-dated programs than before. It's a lot easier for companies to take a three-to-six-month view rather than a 12-month or two-year view.&#8221;
<h2 class="wp-block-heading">Conclusion</h2>
Share buybacks remain a powerful tool for enhancing shareholder value but require careful consideration of the associated risks and challenges. Issuers must navigate complex regulatory landscapes, manage relationships with executing brokers, and anticipate potential disruptions to their business environment. By adopting flexible, strategically aligned approaches, companies can optimize the benefits of buyback programs while mitigating their downside risks. As financial markets continue to evolve, the ability to adapt and innovate will be crucial for success in this domain.

Share Buybacks And Their Complexities

Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) posted better-than-expected results for its <a href="https://www.benzinga.com/quote/SAIA/earnings">fourth quarter on Monday</a>.
The company posted GAAP earnings of $2.84 per share, beating market estimates of $2.80 per share. The company's quarterly sales came in at $788.952 million versus expectations of $786.523 million.
Saia President and CEO, Fritz Holzgrefe, commented on the year stating, &#8220;I am pleased with the progress we made this year, as we opened 21 new terminals and relocated 9 others, further enhancing our service offerings in both new and existing markets. We are proud to bring our 100th year in operation to a close with 214 terminals and our ability to provide direct service to all 48 contiguous states, positioning us as a leading national carrier. We remain focused on operational excellence and are pleased with customer acceptance thus far. We onboarded approximately 1,300 new team members during the year and closed 2024 with over 15,000 employees company-wide.&#8221;
Saia shares gained 0.6% to trade at $473.12 on Tuesday.
These analysts made changes to their price targets on Saia following earnings announcement.
<ul>
<li>B of A Securities analyst Ken Hoexter maintained Saia with a Buy and lowered the price target from $600 to $565.</li>
<li>Wells Fargo analyst Christian Wetherbee maintained the stock with an Equal-Weight rating and lowered the price target from $550 to $510.</li>
<li>JP Morgan analyst Brian Ossenbeck maintained the stock with an Overweight and lowered the price target from $566 to $558.</li>
<li>Susquehanna analyst Bascome Majors maintained Saia with a Neutral and raised the price target from $530 to $540.</li>
<li>Raymond James analyst Patrick Tyler Brown maintained the stock with an Outperform rating and lowered the price target from $560 to $540.</li>
</ul>
Considering buying SAIA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04112904/image-25-1024x581.png" alt="" class="wp-image-765184" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04112904/image-25-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04112904/image-25-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04112904/image-25-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04112904/image-25.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Markets

These Analysts Revise Their Forecasts On Saia After Q4 Results

Rumors

DOMO

Watching Domo; Traders Circulate Stock Picked By Zacks Under $10 Newsletter

Fabrinet shares are trading lower after JP Morgan cut its price target on the stock from $275 to $265.

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Equal-Weight and lowers the price target from $158 to $147.

Morgan Stanley Maintains Equal-Weight on Advanced Micro Devices, Lowers Price Target to $147

Marathon Says To Operate Refineries At 85% Of Capacity In Q1 2025

Citigroup analyst Jason Bazinet maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Neutral and lowers the price target from $163 to $139.

Citigroup Maintains Neutral on Electronic Arts, Lowers Price Target to $139

JJSF

J&J Snack Foods shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

B of A Securities analyst Michael Feniger upgrades Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) from Underperform to Neutral and raises the price target from $73 to $78.

Upgrades

B of A Securities Upgrades Timken to Neutral, Raises Price Target to $78

FirstService Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FSV#TSX">FSV</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) ("FirstService") announced today that its Board of Directors has approved a 10% increase in the quarterly cash dividend on the outstanding Common Shares of the Company and declared a quarterly dividend of US$0.275 per Common Share, up from the previous US$0.25 per Common Share. The dividend is payable on April 7, 2025 to holders of Common Shares of record at the close of business on March 31, 2025.

TSX:FSV

FirstService Increases Quarterly Cash Dividend From $0.25 To $0.275 Per Share

Universe Pharmaceuticals shares are trading lower after the company announced a nasdaq delisting notice.

SenesTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>), a pioneer in humane pest control solutions, is pleased to announce its plans to enter the Indian rodent pest control market through a partnership with SMark, a well-established distributor based in India. The partnership is cemented by a recently signed letter of intent, underscoring the shared commitment to bringing innovative, non-lethal rodent control solutions to this rapidly growing market.
India presents a significant opportunity for rodent pest control solutions, with an estimated market size exceeding $81 million, growing at over 10% annually, and driven by rapid urbanization, agriculture demand, and public health concerns. Rodent infestations impact food supply chains, damage infrastructure, and pose serious health risks, highlighting the critical need for advanced, sustainable pest management strategies.

Global

SNES

SenesTech Announced Entry Into Indian Rodent Pest Control Market Via Partnership With SMark; Market Growing 10% Annually

Predictive Oncology (POAI – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The...

H.C. Wainwright downgrades Predictive Oncology (POAI) to a Hold

H.C. Wainwright downgraded Predictive Oncology (POAI) to Neutral from Buy without a price target after the company started working with a strategic...

Predictive Oncology downgraded to Neutral from Buy at H.C. Wainwright

Predictive Oncology (POAI) announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024. As par...

Predictive Oncology engaged in 'productive discussions' with multiple parties

09:05 EST Predictive Oncology (POAI) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Predictive Oncology Inc trading halted, news pending

Renovaro to acquire Predictive Oncology in all-stock transaction

Predictive Oncology (POAI) announced that it has entered into a binding letter of intent with Renovaro (RENB) for Predictive Oncology to be acquire...

Predictive Oncology to be acquired by Renovaro

09:50 EST Predictive Oncology (POAI) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Predictive Oncology Inc trading resumes

Renovaro (RENB) issued a letter to shareholders from Chief Executive Officer David Weinstein. "As we enter the new year, I wanted to update you on ...

Renovaro BioSciences issues shareholder letter, provides corporate update

Predictive Oncology (POAI) announced plans to launch its validated flagship live cell ChemoFx drug response assay in Europe and expanded availabili...

Predictive Oncology announces planned European launch of ChemoFx

Predictive Oncology to launch ChemoFx drug response assay in Europe

POAI

RENB

Press Releases

Renovaro Issues Shareholder Letter and Provides Corporate Update

Legal

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RHE, FUBO, POAI on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Predictive Oncology Inc. - POAI

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

Comments

Predictive Oncology

ニュース

最新ニュース Predictive Oncology (NASDAQ:POAI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル